Szpital Wojewodzki W Opolu Sp. z o.o. — Clinical Trial Site

14 Registered trials

6 Currently recruiting

Organisation

Szpital Wojewodzki W Opolu Sp. z o.o.

Location

Opole, Poland

Identifier

ORG-100048905

Address

Ul. Katowicka 64, 45-061, Poland

Departments

#8002; Oddzial Kliniczny Hematologii, Onkologii Hematologicznej i Chorob Wewnetrznych
Department of Hematology, Hematological Oncology and Internal Medicine
Oddzial Hematologii i Onkologii Hematologicznej
Oddzial Kliniczny Hematologii, Onkologii Hematologicznej i Chorob Wewnetrznych
Oddział Kliniczny Hematologii, Onkologii Hematologicznej i Chorób Wewnętrznych

Clinical trials at this site (14)

Search interface

Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
This study is to find out the safety and effectiveness of Epcoritamab together with R-CHOP (rituximab, cyclophosphamide, doxorubicin HCL, vi… Recruiting

2023-505277-32-00 Diffuse Large B-Cell Lymphoma (DLBCL) 5 2023-01-26
A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell… Recruiting

2024-516234-35-00 Relapsed or Refractory B-Cell Malignancies 9 2025-10-15
An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent α- or β-thalassemi… Recruiting

2023-507396-21-00 transfusion-dependent α- or β-thalassemia or low-risk m 4 2023-03-16
A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients with Plasma C… Recruiting

2024-515273-10-00 Relapsed or refractory Multiple Myeloma (r/r MM) 7 2021-10-19
PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES Recruiting

2024-518454-17-00 relapsed/refractory hematologic malignancies 1 2021-01-08
A Phase 2a, Randomized, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of sapablurs… Ended

2024-512482-14-00 Polycythemia Vera 4 2023-06-21
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-… Ended

2023-506871-88-00 Relapsed/Refractory Multiple Myeloma 3 2022-10-07
A Combination of Acalabrutinib with R-CHOP in Subjects with previously untreated non-GCB DLBCL Ended

2023-509358-72-00 Diffuse large B-cell lymphoma 5 2020-11-23
KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treat… Ended

2024-513912-89-00 Primary Or Secondary (Post-PV MF or Post-ET-MF) Myelofi 10 2018-12-13
Extended Access of Momelotinib for Subjects with Myelofibrosis Ended

2023-508018-41-00 Primary Myelofibrosis (PMF), Post-polycythemia Vera or 4 2018-07-27
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP 196 in Combination with Obi… Ended

2023-509348-84-00 Chronic Lymphocytic Leukemia 5 2015-04-27
Phase I/II, First in Human, Dose Escalation Trial of TL-895 Monotherapy in Subjects with Relapsed/Refractory B-Cell Malignancies and Expansi… Ended

2024-516691-14-00 B Cell Malignancies and Chronic Lymphocytic Leukemia or 7 2021-01-05
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunoch… Ended

2023-507498-16-00 Diffuse Large B-Cell Lymphoma (DLBCL) 9 2019-07-02